metaLead Therapeutics
metaLead is a spin-out from the University of Zurich pioneering innovative therapies for metal-related diseases. Our platform develops first-in-class metal-binding peptides with exceptional affinity and selectivity to desired metals. Our lead program addresses Wilson disease, a rare genetic condition causing the accumulation of toxic amounts of copper in the liver and brain. We combine cutting-edge science, drug development expertise, and patient-driven innovation.
Date, time and room information
May 6, 13:15 - 13:30, room Singapore
Category
Emerging biotech company
Title of the presentation
Short peptides as effective treatment for Wilson disease
Speaker information
| Name | Position | Institution |
|---|---|---|
| Michal Shoshan | Chief Executive Officer |
Host and event manager:
Logistics and marketing partner:
